Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-GD2 3F8 Antibody and GM-CSF for High-Risk Neuroblastoma
NCT00072358Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2003
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of anti-GD2 monoclonal antibody 3F8 in neuroblastoma (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Efficacy at Completion of Treatment at 3 years and Relapse-free Survival Every 3 Months at 3 years. Started Jul 2003; status: completed.
02
Drugs
anti-GD2 monoclonal antibody 3F8
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00072358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072358.